Kyprolis 60mg Injection

About

Carfilzomib is a proteasome inhibitor indicated for the treatment of multiple myeloma. It works by selectively and irreversibly binding to the N-terminal threonine-containing active sites of the 20S proteasome, a multi-catalytic proteinase complex responsible for degrading ubiquitinated proteins. Inhibition of the proteasome leads to an accumulation of polyubiquitinated proteins within the cell, which can trigger apoptosis, particularly in malignant plasma cells. This mechanism disrupts cellular homeostasis, leading to cell cycle arrest and programmed cell death in cancer cells, while sparing healthy cells to a greater extent. Carfilzomib is often used in patients who have received prior therapies, either as monotherapy or in combination with other anti-myeloma agents.

Uses

• Relapsed or refractory multiple myeloma
• Multiple myeloma in combination with other agents
• Patients who have received at least one prior therapy
• As part of a comprehensive treatment strategy for myeloma

Directions For Use

This medication is administered as an intravenous infusion by a healthcare professional. The dosage and frequency will be determined by your doctor based on your condition and response to treatment.

Benefits

• Effective in treating relapsed and refractory multiple myeloma.
• Induces significant and durable responses in patients.
• Can be used in combination to enhance efficacy.
• Offers a targeted mechanism of action against cancer cells.
• Improves progression-free survival in eligible patients.
• Provides a treatment option for patients with limited alternatives.

Side Effects

• Fatigue
• Nausea
• Diarrhea
• Constipation
• Thrombocytopenia
• Anemia
• Neutropenia
• Dyspnea (shortness of breath)
• Hypertension
• Peripheral edema
• Cardiac events (e.g., heart failure)
• Infusion-related reactions

Safety Measures

• Alcohol - Avoid or limit alcohol consumption as it may exacerbate certain side effects like fatigue or gastrointestinal issues, and potentially interact with the medication.
• Pregnancy - Carfilzomib can cause fetal harm. Women of childbearing potential must use effective contraception during treatment and for a period after.
• Breastfeeding - It is unknown if carfilzomib is excreted in human milk. Due to the potential for serious adverse reactions, breastfeeding is not recommended.
• Liver - Use with caution in patients with moderate to severe liver impairment; dose adjustments may be necessary, and liver function should be monitored.
• Kidney - Dose adjustments may be required for patients with severe renal impairment. Close monitoring of kidney function is essential.
• Lung - Monitor for new or worsening pulmonary symptoms, including dyspnea, cough, or interstitial lung disease, which can be serious.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.